Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCAB NASDAQ:CLRB NASDAQ:KZIA NASDAQ:MYNZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCABBioAtla$3.44+3.9%$4.57$3.12▼$71.50$5.48M0.7947,251 shs54,016 shsCLRBCellectar Biosciences$2.36-6.0%$2.88$2.33▼$13.95$20.06M0.52215,879 shs192,744 shsKZIANovogen$11.42+0.2%$11.41$4.86▼$17.40$18.85M2.17196,495 shs81,848 shsMYNZMainz Biomed$2.20-5.6%$1.34$0.55▼$4.43$19.93M0.31371,589 shs1.92 million shsMissed the SpaceX IPO? Buy These 7 Stocks InsteadThe space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCABBioAtla-0.60%-6.23%-31.61%-61.53%-86.26%CLRBCellectar Biosciences-3.09%-15.49%-19.03%-17.70%-76.81%KZIANovogen+3.73%-9.24%-21.05%+33.80%+101.77%MYNZMainz Biomed0.00%-14.06%+505.39%+166.02%+6.02%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCABBioAtla$3.44+3.9%$4.57$3.12▼$71.50$5.48M0.7947,251 shs54,016 shsCLRBCellectar Biosciences$2.36-6.0%$2.88$2.33▼$13.95$20.06M0.52215,879 shs192,744 shsKZIANovogen$11.42+0.2%$11.41$4.86▼$17.40$18.85M2.17196,495 shs81,848 shsMYNZMainz Biomed$2.20-5.6%$1.34$0.55▼$4.43$19.93M0.31371,589 shs1.92 million shsMissed the SpaceX IPO? Buy These 7 Stocks InsteadThe space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCABBioAtla-0.60%-6.23%-31.61%-61.53%-86.26%CLRBCellectar Biosciences-3.09%-15.49%-19.03%-17.70%-76.81%KZIANovogen+3.73%-9.24%-21.05%+33.80%+101.77%MYNZMainz Biomed0.00%-14.06%+505.39%+166.02%+6.02%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCABBioAtla 2.00Hold$200.005,713.95% UpsideCLRBCellectar Biosciences 2.50Moderate Buy$11.00366.10% UpsideKZIANovogen 2.50Moderate Buy$21.0083.89% UpsideMYNZMainz Biomed 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest BCAB, MYNZ, CLRB, and KZIA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026BCABBioAtla Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/15/2026CLRBCellectar Biosciences LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy5/5/2026CLRBCellectar Biosciences Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.004/21/2026KZIANovogen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CLRBCellectar Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/15/2026KZIANovogen LaidlawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$25.003/10/2026CLRBCellectar Biosciences Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy(Data available from 6/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCABBioAtla$2M2.86N/AN/A($28.51) per share-0.12CLRBCellectar BiosciencesN/AN/AN/AN/A$1.89 per shareN/AKZIANovogen$30K628.10N/AN/A($5.34) per share-2.14MYNZMainz Biomed$659.94K30.20N/AN/A$2.61 per share0.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCABBioAtla-$59.61M-$41.72N/AN/AN/AN/AN/A-325.64%8/6/2026 (Estimated)CLRBCellectar Biosciences-$21.79M-$6.66N/AN/AN/AN/A-349.24%-153.18%8/13/2026 (Estimated)KZIANovogen-$13.41MN/AN/AN/AN/AN/AN/AN/AN/AMYNZMainz Biomed-$21.65M-$65.60N/AN/AN/AN/AN/AN/AN/ALatest BCAB, MYNZ, CLRB, and KZIA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026BCABBioAtla-$10.00-$4.22+$5.78-$4.22$1.72 millionN/A5/14/2026Q1 2026CLRBCellectar Biosciences-$1.8850-$1.33+$0.5550-$1.33$8.00 millionN/A3/31/2026Q4 2025BCABBioAtla-$18.00-$8.00+$10.00-$8.00$0.70 million$2.00 million3/19/2026Q2 2026KZIANovogenN/A-$1.34N/A-$1.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCABBioAtlaN/AN/AN/AN/AN/ACLRBCellectar BiosciencesN/AN/AN/AN/AN/AKZIANovogenN/AN/AN/AN/AN/AMYNZMainz BiomedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCABBioAtlaN/A0.150.15CLRBCellectar BiosciencesN/A1.901.90KZIANovogenN/A2.87N/AMYNZMainz Biomed0.440.520.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCABBioAtla77.23%CLRBCellectar Biosciences16.41%KZIANovogen30.89%MYNZMainz BiomedN/AInsider OwnershipCompanyInsider OwnershipBCABBioAtla9.34%CLRBCellectar Biosciences2.58%KZIANovogen1.00%MYNZMainz Biomed18.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCABBioAtla601.66 million1.50 millionOptionableCLRBCellectar Biosciences107.99 million7.79 millionNo DataKZIANovogen121.65 million1.64 millionNo DataMYNZMainz Biomed309.06 million7.41 millionNot OptionableBCAB, MYNZ, CLRB, and KZIA HeadlinesRecent News About These CompaniesMainz Biomed (NASDAQ:MYNZ) Stock Price Down 5.3% - What's Next?June 6 at 2:09 AM | americanbankingnews.comMainz BioMed NV: Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors / Name change to Quantum Cyber (QUCY)March 12, 2026 | finanznachrichten.deStrategische Neuausrichtung: Mainz Biomed firmiert in Quantum Cyber um und ernennt neuen ChairmanMarch 11, 2026 | de.investing.comMainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of DirectorsMarch 11, 2026 | globenewswire.comMainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood SamplesFebruary 24, 2026 | markets.businessinsider.comMainz Biomed sichert sich 6 Millionen US-Dollar und richtet Fokus auf BauchspeicheldrüsenkrebsFebruary 17, 2026 | de.investing.comMainz Biomed secures $6 million private placement, shifts focus to US pancreatic cancer programFebruary 17, 2026 | msn.comMainz Biomed Announces 6.0 USD Million Private Placement and Strategic UpdateFebruary 17, 2026 | finance.yahoo.comMainz Biomed nimmt 2,15 Mio. US-Dollar über At-the-Market-Platzierung ein/nFebruary 10, 2026 | de.investing.comMainz Biomed Aktie: Neue Studiendaten vorausFebruary 7, 2026 | stock-world.deSMainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual MeetingJanuary 14, 2026 | globenewswire.comMainz Biomed expects to complete eAArly DETECT 2 study in 2026January 6, 2026 | msn.comMainz Biomed Provides Review of 2025 HighlightsJanuary 5, 2026 | markets.businessinsider.comMainz Biomed Initiates eAArly DETECT 2 Clinical Study to Evaluate Next Generation Colorectal Cancer Test and Advances Pancreatic Cancer Screening ProgramJanuary 5, 2026 | quiverquant.comQ2 Small-Cap Biotechs That Could Reward Patient Investors (MYNZ)...December 12, 2025 | marketbeat.comMainz Biomed files $150M mixed securities shelfDecember 5, 2025 | msn.comMainz Biomed announces ColoAlert added to portfolio of DoctorBoxDecember 2, 2025 | msn.comDoctorBox Adds Mainz Biomed’s ColoAlert(R) to Its PortfolioDecember 2, 2025 | markets.businessinsider.comMainz BioMed NV: Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South AmericaNovember 18, 2025 | finanznachrichten.deMainz Biomed, OncoVanguard8 agree to bring ColoAlert to South AmericaNovember 18, 2025 | msn.comMainz Biomed Signs Memorandum of Understanding with OncoVanguard8 to Launch ColoAlert® Colorectal Cancer Screening in South AmericaNovember 18, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCAB, MYNZ, CLRB, and KZIA Company DescriptionsBioAtla NASDAQ:BCAB$3.44 +0.13 (+3.93%) Closing price 04:00 PM EasternExtended Trading$3.48 +0.04 (+1.02%) As of 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.Cellectar Biosciences NASDAQ:CLRB$2.36 -0.15 (-5.98%) Closing price 04:00 PM EasternExtended Trading$2.40 +0.04 (+1.91%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Novogen NASDAQ:KZIA$11.42 +0.02 (+0.18%) Closing price 04:00 PM EasternExtended Trading$11.52 +0.11 (+0.92%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.Mainz Biomed NASDAQ:MYNZ$2.20 -0.13 (-5.58%) As of 06/5/2026Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Corning Is Paving AI's Future With Glass The J.M. Smucker Company’s Dividend: Too Sweet to Ignore? Why's Amazon Suddenly Lagging the S&P 500, and Is It a Warning? Apple's Siri AI Was Finally Announced, So Why Is the Stock Tanking? From Crypto to AI: Insiders Are Trading These 3 Stocks The Case for Intel Over Pure-Play Quantum Firms Has Temu-Owner PDD's Story Changed After Double Miss? Campbell's Soup Stock: Deep Value and a 7% Dividend Yield Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
